Search
for
Sort by
Research 271–300 of 776
- Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
- Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia?
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- Enhanced Insights into Frontal Fibrosing Alopecia: Advancements in Pathogenesis Understanding and Management Strategies
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
- Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Novedades terapéuticas en tricología
- Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima
- Novel therapies for alopecia areata: The era of rational drug development
- Janus kinase inhibitors for alopecia areata
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- Alopecia Areata and Alopecia Areata Incognita
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris